2024-516357-46-00招募中2 期
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.
Philogen S.p.A.2 个研究点 分布在 2 个国家目标入组 70 人开始时间: 2025年3月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- For Phase I the following primary safety endpoints will be considered: − Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.
研究概览
简要总结
The purpose of this study is to explore the safety profile and establish a recommended dose (RD) for phase II of the antibody-cytokine fusion protein L19TNF plus standard TMZ chemoradiotherapy in patients with newly diagnosed glioblastoma. The primary objective of the phase II part of the study is to investigate the efficacy profile of the antibody-cytokine fusion protein L19TNF plus standard chemoradiotherapy in patients with newly diagnosed glioblastoma. The primary objective of the phase IIb part of the study is to investigate the efficacy profile of the antibody-cytokine fusion protein L19TNF plus standard chemoradiotherapy in patients with newly diagnosed glioblastoma.
研究设计
- 分配方式
- Randomized
- 主要目的
- Phase IIb part: Activity Evaluation
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female, age ≥18
- •Patients with histologically confirmed newly diagnosed glioblastoma
- •Karnofsky Performance Score (KPS) ≥ 70%
- •Documented negative test for HIV-HBV-HCV. For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible
- •Female patients: negative pregnancy test for women of childbearing potential (WOCBP)* within 14 days of starting treatment. WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormonereleasing systems, bilateral tubal occlusion or vasectomized partner. *Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).
- •Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.
- •Personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- •Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures
排除标准
- •Prior treatment for glioma, except surgery
- •Active or history of autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent
- •History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris
- •Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria)
- •Clinically significant cardiac arrhythmias or requiring permanent medication
- •Abnormal LVEF or any other abnormalities observed during baseline ECG and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current or a history of QT/QTc prolongation are excluded
- •Uncontrolled hypertension
- •Known arterial aneurism at high risk of rupture
- •Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification)
- •Medically documented history of, or active, major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others), or patients with active severe personality disorders
- •Anxiety ≥ CTCAE Grade 3
- •Inability to undergo contrast-enhanced MRI
- •Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy
- •Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 3 weeks of administration of study treatment
- •Known history of tuberculosis
- •Pregnancy or breast feeding
- •Requirement of chronic administration of high dose corticosteroids or other immunosuppressant drugs. Subjects must have been either off corticosteroids, or on a stable or decreasing dose ≤ 4 mg daily dexamethasone (or equivalent), for 7 days prior to start of chemoradiotherapy. Limited or occasional use of corticosteroids to treat or prevent acute adverse reactions is not considered an exclusion criterion
- •Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study
- •Concurrent malignancies unless the patient has been disease-free without intervention for at least 2 years
- •Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment
- •Serious, non-healing wound, ulcer, or bone fracture
- •Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months
- •Intent to be treated with tumor-treating fields prior to progression
- •Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin)
- •Requirement of concurrent use of other anti-cancer treatments or agents other than study medication
- •Any recent live vaccination within 4 weeks prior to treatment or plan to receive vaccination during the study
- •Known history of allergy to TNF or TMZ, any excipient in the study medication or any other intravenously administered human proteins/peptides/antibodies
- •Absolute neutrophil count (ANC) < 1.5 x 10^9/L, platelets < 100 x 10^9/L or haemoglobin (Hb) < 9.0 g/dl.
- •Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min or serum creatinine > 1.5 ULN
- •Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN or total bilirubin ≥ 2.0 x ULN).
- •INR > 1.5 ULN
- •Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator
结局指标
主要结局
For Phase I the following primary safety endpoints will be considered: − Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.
For Phase I the following primary safety endpoints will be considered: − Occurrence of dose limiting toxicity (DLT) assessed by frequency and grade of adverse events (AE) according to CTCAE v.5.0.
For Phase II the following primary endpoint will be considered: − Overall survival (OS) rate at 12 months (52 weeks).
For Phase II the following primary endpoint will be considered: − Overall survival (OS) rate at 12 months (52 weeks).
For Phase IIb the following primary endpoint will be considered: − Overall survival (OS)
For Phase IIb the following primary endpoint will be considered: − Overall survival (OS)
次要结局
- For Phase I the following secondary safety endpoints will be considered: − Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19TNF. − Pharmacokinetic characterization of L19TNF. The following secondary efficacy endpoints will be considered: − Progression-free survival (PFS) based on iRANO criteria and a standardized MRI protocol. − Overall survival (OS) rate at 12 months (52 weeks). − OS. − Objective Response Rate (ORR, consisting of complete
- For Phase II the following secondary efficacy endpoints will be considered: − PFS based on iRANO criteria and a standardized MRI protocol. − OS − ORR (consisting of CR and PR) at Week 10, at Week 22, at Week 34, at Week 46 and at Week 58 − BORR The following secondary safety endpoints will be considered: − Frequency and grade of AEs, SAE and DILI according to CTCAE v.5.0 − Assessment of the formation of HAFA against L19TNF − Pharmacokinetic characterization of L19TNF
- For Phase IIb The following secondary efficacy endpoints will be considered: − PFS based on iRANO criteria based on standardized MRI protocol. − OS rate at 12 months (52 weeks) − ORR and DCR at Week 10, at Week 22, at Week 34, at Week 46 and at Week 58 − BORR The following secondary safety endpoint will be considered: − Frequency and grade of AEs, SAEs and DILI according to CTCAE v.5.0. − Assessment of the formation of HAFA against L19TNF. − PK characterization of L19TNF.
研究者
Teresa Hemmerle
Scientific
Philogen S.p.A.
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479Molecular Partners AG138
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60
招募中
2 期
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in breast cancer, with positive hormone receptors and negative HER2 status, in newly diagnosed, not immediately operable (or wishing to avoid surgery), elderly patientbreast cancer2022-501527-24-00Centre Antoine Lacassagne85
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy2024-511853-23-00Oncoinvent ASA54